• 0.4% Trypan Blue Solution: Technical Guide for Cell Viabilit

  2026-04-24

  0.4% Trypan Blue Solution provides a reliable method for distinguishing live from dead cells in research workflows, supporting accurate cell viability measurement and cell counting. It is not suitable for diagnostic or clinical use and should only be applied within validated cell culture, viability, and cytotoxicity assay protocols.

• Norovirus Hijacks NINJ1 for Selective Viral Protein Secretio

  2026-04-24

  Song et al. reveal that murine norovirus (MNoV) co-opts the host protein NINJ1 to enable selective secretion of its NS1 protein, exploiting a regulated cell death pathway. This discovery clarifies mechanisms of unconventional protein secretion during viral infection and highlights new intersections between virology and programmed cell death.

• ML133 HCl: Potassium Channel Inhibitor for PASMC Research

  2026-04-23

  ML133 HCl stands out as a selective potassium channel inhibitor, enabling precise inhibition of Kir2.1 channels in pulmonary artery smooth muscle cell research. Leveraging robust selectivity and workflow-validated protocols, it empowers cardiovascular and vascular remodeling studies with high reproducibility and actionable insights.

• 17-AAG (Tanespimycin): Applied HSP90 Inhibition in Cancer Mo

  2026-04-23

  17-AAG (Tanespimycin) from APExBIO empowers researchers to achieve precise HSP90 chaperone inhibition and robust client protein degradation across diverse cancer models. This guide delivers stepwise workflows, advanced troubleshooting, and actionable insights—bridging foundational protocols with emerging discoveries in regulated cell death and membrane dynamics.

• Palonosetron Hydrochloride: Reliable 5-HT3 Antagonist for La

  2026-04-22

  This article presents scenario-driven insights for researchers using Palonosetron hydrochloride (SKU B2229) in cell viability and transporter assays. We address common experimental challenges, protocol optimization, and product selection, highlighting how APExBIO’s high-purity formulation ensures reproducibility and robust data for 5-HT3 receptor and transporter studies.

• Homoharringtonine: Mechanistic Innovation for Translational

  2026-04-22

  This thought-leadership article explores Homoharringtonine’s dual-action as a cytotoxic alkaloid, offering mechanistic insight and strategic guidance for translational researchers in cancer biology and antiviral studies. Highlighting its ribosomal inhibition, rapid SARS-CoV-2 clearance, and practical protocol parameters, the article contextualizes APExBIO’s Homoharringtonine (SKU N1504) as a uniquely validated research tool. By bridging competitive landscape analysis and workflow recommendations, it delivers actionable perspectives for the scientific community.

• Tubastatin A: HDAC6 Inhibition Redefines Translational Resea

  2026-04-21

  Tubastatin A, a highly selective HDAC6 inhibitor from APExBIO, is revolutionizing translational research by bridging epigenetic mechanisms, cell death modulation, and therapeutic innovation. This thought-leadership article integrates mechanistic insights, recent preclinical validation, and strategic guidance for researchers seeking to unlock new dimensions in cancer biology, neuroprotection, and inflammation. By contextualizing Tubastatin A’s unique capabilities within the evolving competitive landscape and referencing both landmark and emerging studies, we chart a path for rigorous, impactful experimentation and cross-domain discovery.

• Partial BACE1 Inhibition Spares Synaptic Function in AD Mode

  2026-04-21

  Satir et al. (2020) demonstrated that partial inhibition of beta-secretase (BACE1) can reduce amyloid-beta production by up to 50% without impairing synaptic transmission in neuron cultures. This study suggests that moderate BACE1 inhibition could be a strategic target for Alzheimer's disease research, balancing efficacy with synaptic safety.

• Norovirus Exploits NINJ1 for Selective Protein Secretion Con

  2026-04-20

  This study uncovers how murine norovirus hijacks the host protein NINJ1 to facilitate the selective secretion of its NS1 protein, a process critical for immune evasion. Using unbiased genetic screening and mechanistic analysis, the authors reveal new paradigms in regulated cell death, viral immune modulation, and unconventional protein secretion.

• Translational Impact of SU5416 (Semaxanib) in Angiogenesis I

  2026-04-20

  This thought-leadership article explores the mechanistic and translational landscape of SU5416 (Semaxanib), a selective VEGFR2 inhibitor, in the context of cancer and vascular disease research. Blending mechanistic insight with actionable guidance, it draws on new evidence, strategic protocol recommendations, and recent biomarker discoveries in pulmonary arterial hypertension (PAH). The narrative critically evaluates how SU5416’s dual actions—angiogenesis inhibition and immune modulation—can be leveraged to advance disease modeling and biomarker validation, with a focus on integrating evidence from recent proteomic studies and APExBIO’s rigorously validated workflows.

• Imipenem in Antibacterial Research: Experimental Workflows &

  2026-04-19

  Imipenem, a semisynthetic thienamycin antibiotic, stands out as a robust tool for antibacterial research, offering broad-spectrum action and unique immune-modulatory properties. This article delivers actionable workflows, protocol refinements, and troubleshooting strategies to help scientists maximize the translational impact of Imipenem across resistance modeling, sepsis animal studies, and PBP-targeted assays.

• Sorafenib (BAY-43-9006): Advanced Mechanisms in Angiogenesis

  2026-04-18

  Explore how Sorafenib (BAY-43-9006) acts as a precise, multi-targeted tool for dissecting angiogenic and proliferative pathways in cancer biology. This article delves into mechanistic insights, key protocols, and novel research advances that set Sorafenib apart from standard antiangiogenic agents.

• Palonosetron Hydrochloride: Advances in CINV Prevention Mech

  2026-04-17

  This article reviews the innovation and clinical significance of palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting (CINV). The reference study highlights palonosetron's unique pharmacological properties among 5-HT3 receptor antagonists and discusses its comparative clinical efficacy and tolerability, providing a detailed resource for researchers in antiemetic therapy.

• Perospirone Inhibits Kv1.5 Channels in Coronary Smooth Muscl

  2026-04-16

  This study demonstrates that Perospirone, an atypical antipsychotic, directly inhibits vascular voltage-gated K+ channels—specifically the Kv1.5 subtype—in coronary arterial smooth muscle cells, independent of its classic serotonergic and dopaminergic actions. These findings highlight a previously unrecognized off-target effect with potential cardiovascular implications for schizophrenia and neuropsychiatric disorder research.

• Shufeng Xingbi Therapy Modulates Immunity and Microbiota in

  2026-04-15

  This study rigorously investigates Shufeng Xingbi Therapy's (SFXBT) impact on Th1/Th2 immune balance and intestinal microbiota in a rat model of allergic rhinitis (AR). By integrating immunological and microbiome analyses, the work provides mechanistic insights into how SFXBT may alleviate airway inflammation through both immune modulation and gut flora shifts.

15574 records 1/1039 page Next 12345 下5页 Last page